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In light of their preeminent role in cellular immunity, there is considerable interest in targeting of cytotoxic T-lymphocytes to cancer.
This review summarises the active and passive immunotherapeutic approaches under development to achieve this goal, emphasising
how recent advances in tumour immunology and gene transfer have impacted upon this field.
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The challenge of developing cancer immunotherapy is one of the
longest standing goals of immunology, dating back to the late 19th
century. Despite many setbacks, recent developments have
rejuvenated the sense of optimism in this quest. Almost 30 years
after their development, monoclonal antibodies are now com-
monly used in the treatment of selected malignancies. While this
represents an important advance, much evidence suggests that
harnessing of the cellular immune system might contribute even
more effectively to this endeavour. The focus of this minireview is
to consider how CD8
þ cytotoxic T lymphocytes (CTL) might be
targeted for cancer immunotherapy.
CYTOTOXIC T LYMPHOCYTES AS EFFECTORS OF
ANTITUMOUR IMMUNITY
Cytotoxic T lymphocytes represent a crucial component of
the adaptive immune system with particular importance in
the control of intracellular pathogens. Effector CTL have the
capacity to promote the apoptotic death of carefully chosen
target cells, using a combination of granule (perforin/granzyme)-
and receptor (Fas/tumour necrosis factor)-mediated mechanisms.
While natural killer cells also promote cell death, CTL are
distinguished by their exquisite specificity for antigen, which
they recognise using a clonally unique T-cell receptor
(TCR). Target cells are ‘flagged’ for the attention of CTL when
they present antigen-derived peptide fragments on the cell surface,
inserted into the groove of class I major histocompatibility (MHC)
molecules.
In addition to cytolytic function, a number of other properties
render CTL attractive as mediators of antitumour immunity. First,
the widespread expression of MHC class I molecules means that
CTL could, in principle, be deployed against malignancies of
diverse origin. Second, CTL (like all lymphocytes) continuously
recirculate throughout the body to seek out antigen, a useful
property for the treatment of systemic disease. Third, target
recognition is impressively sensitive – even a single peptide–MHC
class I complex may trigger cytolysis by a high-avidity effector CTL
(Sykulev et al, 1996). Finally, CTL also employ nonlytic effector
mechanisms including the production of interferon gamma – a
cytokine with several direct and indirect antitumour properties
(Qin et al, 2003).
In light of their lethal payload, generation of effector
CTL is tightly regulated and depends upon the antigen-driven
differentiation of naı ¨ve CD8
þ T cells. This process is initiated
when dendritic cells (DC) take up antigen within peripheral
tissues and migrate to the regional lymph nodes. Here, DC
are ideally placed to interact with naı ¨ve T lymphocytes,
which preferentially recirculate through secondary lymphoid
tissue. In order to achieve optimum CTL priming, DC
must be in an activated (‘licensed’) state. This is generally
achieved when DC present processed antigen to MHC class
II-restricted CD4
þ (helper) T cells – the latter then upregulate
CD40 ligand that engages DC-associated CD40. Alternatively, DC
may be licensed in response to some proinflammatory cytokines or
bacterial products that engage Toll-like receptors (Lanzavecchia,
1998).
To achieve optimum expansion of CTL, two additional
requirements should be met. First, since CD4
þ and CD8
þ T cells
are restricted by different MHC families, it is desirable that DC
process antigen to enable presentation of derived epitopes both by
MHC class I and II. Second, appropriate costimulatory signals
must be provided (‘signal 2’) to complement that delivered by the
TCR (‘signal 1’). These accessory signals are delivered by several
ligands, many of which are upregulated on licensed DC. The best
characterised of these are the members of the B7 family, which
engage T-cell-associated CD28. Under some circumstances, the
resultant clonal expansion of CTL is quite remarkable. In the
context of some acute viral infections, CTL of a single specificity
may account for more than 40% of peripheral blood CD8
þ T cells
(Callan et al, 1998).
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To counteract the attention of CTL and other effector arms of the
immune system, cancer cells deploy several immune evasion
strategies (summarised in Figure 1). Many of these diversionary
tactics rely upon the ability of cancer cells to harness systems that
maintain immune tolerance to self. Immune tolerance is mediated
in part by deletion of autoreactive lymphocytes, although this
would be difficult to reverse using an immunotherapeutic
approach. By contrast, nondeletional tolerance mechanisms may
in principle prove more amenable to therapeutic manipulation.
For example, increasing evidence has implicated a number of
regulatory T-cell subsets in the maintenance of immune tolerance
both to self and to derived malignancies. These include CD4
þ
CD25
þ Treg cells, IL-10-producing Tr1 cells, transforming growth
factor (TGF)-b-producing Th3 cells and CD8
þ regulatory T-cell
subsets (Nelson, 2004). In light of this, it is conceivable that the
depletion or suppression of such cellular populations might
provide a useful adjunct in the immunotherapy of malignant
disease.
VACCINATION STRATEGIES THAT TARGET CTL TO
TUMOUR ANTIGENS
In principle, CTL may be targeted to cancer using one of two
approaches, based upon the classical establishment of active or
passive immunity. The greatest success of clinical immunology has
been the development of vaccines for the prophylaxis of infectious
disease. Indeed, some such vaccines are proving useful in the
prevention of virus-related malignant disorders, notably hepatoma
(Chang et al, 1997). The majority of infectious disease vaccines
achieve host immunity since they elicit a protective antibody
response. By contrast, most tumour vaccines have focused upon
the induction of tumour-reactive CTL.
One traditional approach to the development of a cancer vaccine
involves the use of inactivated whole tumour cells (or derived
extracts – Figure 2A). More recently, this approach has been
extended with the development of tumour cell-based vaccines
engineered to express immunomodulatory cytokines and/or
costimulatory ligands (e.g. following genetic modification or
fusion with DC). An important difficulty with the use of such
complex vaccines is the fact that relevant antigens are often
obscure and thus in vitro immune monitoring may prove difficult.
In recent years, the scientific rationale underlying tumour
vaccination has been strengthened enormously by the demonstra-
tion that nonviral malignancies express tumour antigens. This
crucial advance, pioneered by Thierry Boon and co-workers (van
der Bruggen et al, 2002), has resulted in the development of
vaccines based upon defined molecular targets. In the majority of
cases, such antigens are targets for CTL and derive from molecules
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Figure 1 Tumours can escape from immune targeting by CTL in several
ways. First, since cancer cells are closely related to ‘self’, they contain a
predominance of poorly immunogenic self-antigen. Second, cancer cells
have poor antigen-presenting properties since they provide limited
costimulation and may downregulate MHC antigen expression. Third, the
tumour microenvironment is frequently rich in cytokines that compromise
DC differentiation (e.g. interleukin (IL)-6, IL-10, macrophage colony-
stimulating factor, vascular endothelial growth factor) or activation,
proliferation and effector function of T lymphocytes (e.g. transforming
growth factor-b). Fourth, cancer cells may acquire resistance to apoptosis, a
key effector mechanism of CTL and other cells of the immune system. Of
related significance, cancer cells may express death receptor ligands (e.g.
Fas ligand) that could facilitate the elimination of tumour-specific T cells
(‘immune counterattack’). Finally, it has been suggested that regulatory T-
cell subsets (for example, CD4
þ CD25
þ Treg cells) promote immune
tolerance to cancer. These cells also produce immunosuppressive cytokines
and express CTLA-4, a molecule with a number of tolerance-promoting
activities.
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Figure 2 To break immune tolerance against cancer, several vaccine-
based strategies are under development. (A) To target a broad spectrum
of antigens, tumour cells may be engineered to secrete immunomodulatory
cytokines, such as GM-CSF, and/or costimulatory ligands (e.g. B7).
Alternatively, whole tumour cell derivatives may be administered together
with an appropriate adjuvant and/or delivery system. (B) Vaccines based
upon discrete tumour antigen(s) may be formulated in several ways – for
example, as naked DNA, protein or derived peptide(s). Since many tumour
antigen-derived peptides bind weakly to MHC, sequence alterations may
be incorporated to increase binding affinity (heteroclitic approach). A
variety of targeting motifs may be fused with such molecular vaccines in an
attempt to direct delivery (for example to dendritic cells) and/or
preferential processing by the MHC class I or class II pathway. (C) Viral
delivery systems are powerfully immunogenic, particularly when live
(attenuated) vectors are used. These agents show particular promise in
‘prime-boost’ strategies, in which antigen is administered sequentially by
distinct means. (D) Dendritic cells are potent antigen-presenting cells that
may be used to deliver tumour antigen in several forms. Whereas
immature DC may promote tolerance, mature DC are highly immunogenic
and may even break tolerance to self-antigen.
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counterparts. The recognition of the close relationship between
tumour antigens and ‘self’ provides a molecular explanation
for one of the key obstacles to the breaking of immune tolerance to
cancer. In light of this difficulty, a very large number of antigen-
specific vaccines are under development (Figure 2B–C),
based upon peptides, protein, mRNA or DNA expressed from
plasmid or viral vectors (Whelan et al, 2003). To enhance
immunogenicity, a range of adjuvants have been tested many of
which promote DC activation. Indeed, an increasing area of study
involves the use of DC-based vaccines engineered to express
antigen (Figure 2D; Cerundolo et al, 2004). Many tumour vaccines
have successfully expanded CTL responses to appropriate antigens
(Coulie and van der Bruggen, 2003). Furthermore, some promising
studies have been reported in experimental animal models,
particularly in the setting of protection from tumour challenge
(Morris et al, 2003).
Recently, several small clinical studies of therapeutic vaccination
have been performed. In general, these trials have confirmed
the safety of the approach and have sometimes demonstrated
induction of CTL and/or antibody responses to vaccine compo-
nents (e.g. Knutson et al, 2001). These findings suggest
that tumours bearing defined antigens can be targeted
immunotherapeutically. Somewhat disappointingly however,
apart from sporadic responses in isolated individuals, clinical
outcomes have generally been disappointing (Finn, 2003; Morris
et al, 2003).
What lessons have been learned that might improve the
effectiveness of tumour vaccination? A key point illustrated by
many animal studies is the relative ineffectiveness of this approach
in the setting of advanced tumour burden. Consequently, it may
prove much more fruitful to test suitable vaccines in patients with
minimal residual disease. A further option is to combine
vaccination with other therapeutic modalities, as recently illu-
strated in acute promyelocytic leukaemia (Padua et al, 2003).
Third, it may be worth developing broadly applicable vaccines that
simultaneously target CTL to multiple tumour-associated epitopes
(Graff-Dubois et al, 2002). In parallel, it is important to determine
why therapeutic vaccination is poorly effective in advanced disease
and to understand those instances where significant responses are
observed. A variety of new techniques permit the monitoring of
antigen-specific CTL responses, including ELISPOT, tetramer
analysis and intracellular cytokine detection (Clay et al, 2001).
While studies to date have only occasionally correlated results of
such assays with clinical responses, this is likely to provide a fertile
area for further research.
ADOPTIVE IMMUNOTHERAPY USING EX VIVO GEN-
ERATED CTL
Passive (adoptive) immunotherapeutic approaches also represent
an attractive means to target CTL to tumour cells. In some in vivo
experimental models, adoptive immunotherapy using amplified
CTL has demonstrated greater success than vaccination ap-
proaches that target the same tumour type (Romieu et al, 1998).
Adoptive immunotherapy generally involves the administration of
large numbers of T cells, thereby bypassing tolerance mechanisms
that limit the activation and expansion of CTL. In clinical practice,
this approach is best illustrated by treatment of some haemato-
logical malignancies with allogeneic stem cell transfer, or donor
leucocyte infusion. In this setting, there is compelling evidence
that CTL and other effector cells deliver a ‘graft vs leukaemia effect’
that contributes importantly to therapeutic efficacy. Transferred
CTL are also of established benefit in the treatment of some virus-
related malignancies, such as Epstein–Barr virus (EBV)-related
post-transplant lymphoproliferative disease (Rooney et al, 2001).
However, evidence that such cellular therapies can achieve
meaningful control of common solid tumours is more limited.
Furthermore, it is well known that allogeneic T cells can mediate
graft vs host disease, with potentially lethal consequences.
Consequently, there is a need to broaden the applicability and
enhance the safety of this approach, preferably with the use of
tumour-specific autologous T lymphocytes.
The development of adoptive T-cell immunotherapy for solid
tumours has been pioneered by Steven Rosenberg and co-workers.
Following the demonstration that IL-2 could achieve responses in a
small number of patients with malignant melanoma, this group
subsequently developed techniques to expand tumour-infiltrating
lymphocytes (TIL) in vitro. When TIL were infused into patients, a
modest improvement in response rate became apparent, although
success was hampered by poor in vivo persistence of transferred
cells (Rosenberg et al, 1994). Over the ensuing years, it has
emerged that TIL are enriched for MHC class I-restricted CTL with
specificity for known melanoma antigens including MART-1 and
gp100. More recently, this group have shown that following
lymphodepletion, TIL undergo impressive IL-2-driven expansion
in vivo, increasing the clinical response rate significantly (Dudley
et al, 2002).
These studies elegantly provide proof of principle for the clinical
potential of adoptive immunotherapy. To translate this approach
more widely, systems are required to achieve the rapid ex vivo
expansion of CTL targeted to relevant tumour antigens. Fortu-
nately, a number of strategies are under development that may
achieve this.
GENETIC APPROACHES TO CTL-BASED ADOPTIVE
IMMUNOTHERAPY
A recent key development has been the application of gene
transfer-based strategies to target CTL to cancer cells. Several
avenues of investigation are under development at this time. One
promising approach involves the use of ‘artificial antigen-
presenting cells’ that permit the in vitro expansion of tumour-
specific CTL (Latouche and Sadelain, 2000). To achieve this,
NIH3T3 fibroblasts have been genetically engineered to express a
chosen peptide epitope, together with an MHC class I molecule, b2
microglobulin and a series of costimulatory ligands. Using this
system, impressive expansion of CTL of the desired specificity can
be achieved. To further boost in vitro CTL expansion, many
groups have demonstrated the potent growth-promoting effect of
IL-15 (e.g. Brentjens et al, 2003).
An alternative approach is to genetically modify T cells or CTL,
thereby retargeting specificity to a chosen tumour antigen (Eshhar,
1997). Most commonly, this is achieved using a ‘chimeric antigen
receptor’ (CAR) in which an antibody-derived single chain
fragment (scFv) is coupled via a hinge to an appropriate signalling
element (Figure 3). Chimeric antigen receptors are generally
expressed on the T-cell surface as a single gene-encoded
homodimer, enabling the MHC-independent recognition of native
tumour-associated antigen. Several such fusion receptors have
been constructed with specificity for molecules expressed by solid
and haematological malignancies (e.g. Eshhar, 1997, Gong et al,
1999).
In most early CAR designs, the signalling domain was chosen
to deliver a surrogate TCR-like stimulus. The CD3z cytoplasmic
domain delivers a potent signal 1 and is well suited for
this purpose. Despite fears about TCR signalling in cancer-
bearing hosts, it is reassuring that CD3z-based CAR retain
potent activity when expressed in T lymphocytes derived from
such patients (Gong et al, 1999; Brentjens et al, 2003; Sheen et al,
2003).
Most tumours do not provide adequate T-cell costimulation.
Consequently, there has been considerable interest in the
development of CAR that provides such accessory signals. An
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fusion receptors (Alvarez-Vallina and Hawkins, 1996). More
recently, CAR have been designed in which the signalling domains
of CD3z and CD28 have been fused in series, creating molecules
that can deliver both a functional signal 1 and signal 2 (Finney et al,
1998). When such ‘second-generation’ CAR are expressed in
human T cells, they can be repeatedly activated in vitro by
coculture with antigen-expressing tumour cells. Each cycle of
stimulation results in rapid death of the tumour targets, followed
by IL-2-driven proliferation of CAR-grafted T cells (Maher et al,
2002). More recently, it has been shown that several alternative
costimulatory domains can be fused in series with CD3z to create
CAR with distinct functional properties (Finney et al, 2004). An
alternative approach to promote sustained survival of CAR-grafted
CTL involves selective gene-transfer into EBV-responsive T cells,
which are known to persist for prolonged periods in vivo (Rossig
et al, 2002). In parallel to these developments, CAR technology has
received an important boost with the demonstration that this
approach can achieve sustained control of an established in vivo
tumour burden (Haynes et al, 2002; Brentjens et al, 2003).
Significantly, those studies have also emphasised the importance of
costimulation.
An alternative genetic strategy involves the introduction of a
new TCR with specificity for a defined, tumour-associated
peptide–MHC complex. A number of in vitro studies have
successfully used this system to redirect the antigenic specificity
of both CD4
þ and CD8
þ T cells. This approach is attractive in
that it allows access to a greater repertoire of protein antigens
than CAR, since the latter requires that the targeted antigen is
expressed on the cell surface. Furthermore, it might be anticipated
that ectopic TCR would prove less immunogenic than CAR
that originate from (nonhumanised) rodent hybridoma-based
scFv. However, these advantages are balanced by some important
disadvantages. Since the TCR is a heterodimer, this strategy
requires the regulated coexpression of two gene products (TCR a
and b chains). In principle, such exogenous receptor subunits
may heterodimerise with endogenous TCR subunits, generating
complexes with autoreactive potential. This potential difficulty
may be overcome by inclusion of sequences that only permit
dimerisation of the ectopic TCR subunits. A second disadvantage
is the frequent downregulation of MHC class I molecules observed
in cancer, providing an opportunity for immune escape from the
genetically modified CTL (Gilboa, 1999). Thirdly, owing to the
highly polymorphic nature of the human MHC (human leucocyte
antigen – HLA) system, ectopic TCR would need to be matched to
the HLA haplotype of the patient, imposing additional logistical
constraints.
An important consideration for all forms of immunotherapy is
the tumour microenvironment, which is frequently poorly
conducive to CTL function (Figure 1). Many malignancies are
associated with overproduction of immunosuppressive cytokines
such as TGF-b, although genetic approaches may be used to
circumvent this (Gorelik and Flavell, 2001). Alternatively, the
microenvironment may be decorated with a suitable immunopo-
tentiating agent, such as the tumour-necrosis factor superfamily
member, LIGHT. Recently, this has been reported to achieve a
dramatic recruitment of naı ¨ve CTL to malignant deposits, where
they are primed and elicit impressive antitumour immunity (Yu
et al, 2004).
The exciting opportunities afforded by genetic modification of T
cells have set the stage for a number of clinical studies that are
currently underway. However, a cautionary note is warranted in
light of the development of leukaemia in two children following
treatment of X-linked severe combined immunodeficiency using
gene-modified haemopoietic stem cells. A full discussion of this
complex issue is beyond the scope of the current review (see Kohn
et al, 2003). It is clear, however, that safety must be paramount in
the clinical testing of such novel treatments. Consequently, it may
be appropriate to include ‘suicide genes’ in adoptively transferred
T cells to allow their elimination when required. The best studied
of these approaches involves expression of the herpes simplex
virus thymidine kinase gene, which renders T cells susceptible to
ganciclovir.
CONCLUSIONS
Recent developments mean that immunotherapy is likely to play
an increasingly important role in cancer therapy. Adoptive
immunotherapy may find its niche in the debulking of disease
that is resistant to conventional therapeutic regimens. By contrast,
vaccination may prove most useful in the context of lower tumour
burden and as a means to attain longer-term immunity and
memory. In both settings, CTL are likely to play a key role,
justifying the widespread interest in targeting of these key immune
effector cells to cancer.
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Figure 3 Antigen recognition by chimeric antigen receptors (CAR) is
most commonly mediated by a single chain antibody fragment, comprising a
variable heavy (VH) and variable light (VL) chain domain, joined with a
short linker (left). In recent CAR designs, the intracellular domain comprises
a modular array of fused signalling elements that together provide a TCR-
like and a costimulatory signal. By contrast, the TCR recognises processed
antigen, presented as a peptide–MHC complex (right). This in turn triggers
signal transduction by the CD3 complex (not shown).
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